{"messages":[{"status":"ok","cursor":"6750","count":30,"total":8966}], "collection":[{"rel_doi":"10.1101\/2020.04.22.056747","rel_title":"Comparison of commercial RT-PCR diagnostic kits for COVID-19","rel_date":"2020-04-24","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.04.22.056747","rel_abs":"The final months of 2019 witnessed the emergence of a novel coronavirus in the human population. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has since spread across the globe and is posing a major burden on society. Measures taken to reduce its spread critically depend on timely and accurate identification of virus-infected individuals by the most sensitive and specific method available, i.e. real-time reverse transcriptase PCR (RT-PCR). Many commercial kits have recently become available, but their performance has not yet been independently assessed.\n\nThe aim of this study was to compare basic analytical and clinical performance of selected RT-PCR kits from seven different manufacturers (Altona Diagnostics, BGI, CerTest Biotec, KH Medical, PrimerDesign, R-Biopharm AG, and Seegene).\n\nWe used serial dilutions of viral RNA to establish PCR efficiency and estimate the 95% limit of detection (LOD95%). Furthermore, we ran a panel of SARS-CoV-2-positive clinical samples (n=16) for a preliminary evaluation of clinical sensitivity. Finally, we used clinical samples positive for non-coronavirus respiratory viral infections (n=6) and a panel of RNA from related human coronaviruses to evaluate assay specificity.\n\nPCR efficiency was [&ge;]96% for all assays and the estimated LOD95% varied within a 6-fold range. Using clinical samples, we observed some variations in detection rate between kits. Importantly, none of the assays showed cross-reactivity with other respiratory (corona)viruses, except as expected for the SARS-CoV-1 E-gene.\n\nWe conclude that all RT-PCR kits assessed in this study may be used for routine diagnostics of COVID-19 in patients by experienced molecular diagnostic laboratories.","rel_num_authors":9,"rel_authors":[{"author_name":"Puck B van Kasteren","author_inst":"National Institute for Public Health and the Environment (RIVM)"},{"author_name":"Bas van der Veer","author_inst":"National Institute for Public Health and the Environment"},{"author_name":"Sharon van den Brink","author_inst":"National Institute for Public Health and the Environment"},{"author_name":"Lisa Wijsman","author_inst":"National Institute for Public Health and the Environment"},{"author_name":"Jorgen de Jonge","author_inst":"National Institute for Public Health and the Environment"},{"author_name":"Anne-Marie van den Brandt","author_inst":"National Institute for Public Health and the Environment (RIVM)"},{"author_name":"Richard Molenkamp","author_inst":"Erasmus University Medical Center"},{"author_name":"Chantal B.E.M. Reusken","author_inst":"National Institute for Public Health and the Environment"},{"author_name":"Adam Meijer","author_inst":"National Institute for Public Health and the Environment"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.04.20.20067512","rel_title":"Rapid identification of SARS-CoV-2-infected patients at the emergency department using routine testing","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.20.20067512","rel_abs":"Background: The novel coronavirus disease 19 (COVID-19), caused by SARS-CoV-2, spreads rapidly across the world. The exponential increase in the number of cases has resulted in overcrowding of emergency departments (ED). Detection of SARS-CoV-2 is based on an RT-PCR of nasopharyngeal swab material. However, RT-PCR testing is time-consuming and many hospitals deal with a shortage of testing materials. Therefore, we aimed to develop an algorithm to rapidly evaluate an individual's risk of SARS-CoV-2 infection at the ED. Methods: In this multicenter retrospective study, routine laboratory parameters (C-reactive protein, lactate dehydrogenase, ferritin, absolute neutrophil and lymphocyte counts), demographic data and the chest X-ray\/CT result from 967 patients entering the ED with respiratory symptoms were gathered. Using these parameters, an easy-to-use point-based algorithm, called the corona-score, was developed to discriminate between patients that tested positive for SARS-CoV-2 by RT-PCR and those testing negative. Computational sampling was used to optimize the corona-score. Validation of the model was performed using data from 592 patients. Results: The corona-score model yielded an area under the receiver operating characteristic curve of 0.91 in the validation population. Patients testing negative for SARS-CoV-2 showed a median corona-score of 3 versus 11 (scale 0-14) in patients testing positive for SARS-CoV-2 (p<0.001). Using cut-off values of 4 and 11 the model has a sensitivity and specificity of 96% and 95%, respectively. Conclusion: The corona-score effectively predicts SARS-CoV-2 RT-PCR outcome based on routine parameters. This algorithm provides the means for medical professionals to rapidly evaluate SARS-CoV-2 infection status of patients presenting at the ED with respiratory symptoms.","rel_num_authors":10,"rel_authors":[{"author_name":"Steef Kurstjens","author_inst":"Jeroen Bosch Ziekenhuis"},{"author_name":"Armando van der Horst","author_inst":"Jeroen Bosch Hospital"},{"author_name":"Robert Herpers","author_inst":"Bernhoven Hospital"},{"author_name":"Mick W.L. Geerits","author_inst":"Abnormal Design Ltd"},{"author_name":"Yvette C.M. Kluiters-de Hingh","author_inst":"Elisabeth TweeSteden Hospital"},{"author_name":"Eva-Leonne G\u00f6ttgens","author_inst":"Amphia Hospital"},{"author_name":"Martinus J.T. Blaauw","author_inst":"Bernhoven Hospital"},{"author_name":"Marc H.M. Thelen","author_inst":"Amphia Hospital"},{"author_name":"Marc G.L.M. Elisen","author_inst":"Elisabeth TweeSteden Hospital"},{"author_name":"Ron Kusters","author_inst":"Jeroen Bosch Ziekenhuis"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.04.24.060376","rel_title":"The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections","rel_date":"2020-04-24","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.04.24.060376","rel_abs":"Coronaviruses belong to a group of enveloped, positive-single stranded RNA viruses that are known to cause severe respiratory distress in animals and humans. The current SARS coronavirus-2 (SARS CoV-2) pandemic has caused more than 2,000,000 infections globally and nearly 200,000 deaths. Coronaviruses enter susceptible cells via fusion of the viral envelope with the plasma membrane and\/or via fusion of the viral envelope with endosomal membranes after endocytosis of the virus into endosomes. Previous results with SARS and MERS CoV have shown that the Spike (S) glycoprotein is a major determinant of virus infectivity and immunogenicity. Herein, we show that expression of SARS CoV-2 S (S-n) glycoprotein after transient transfection of African green monkey kidney (Vero) cells caused extensive cell fusion in comparison to limited cell fusion caused by the SARS S (S-o) glycoprotein. S-n expression was detected intracellularly and on transfected Vero cell surfaces and caused the formation of very large multinucleated cells (syncytia) by 48 hours post transfection. These results are in agreement with published pathology observations of extensive syncytial formation in lung tissues of COVID-19 patients. This differential S-n versus S-o-mediated cell fusion suggests that SARS-CoV-2 is able to spread from cell-to-cell much more efficiently than SARS effectively avoiding extracellular spaces and neutralizing antibodies. A systematic screening of several drugs for ability to inhibit S-n and S-o cell fusion revealed that the FDA approved HIV-protease inhibitor, nelfinavir mesylate (Viracept) drastically inhibited S-n and S-o-mediated cell fusion in a dose-dependent manner. Complete inhibition of cell fusion was observed at a 10 micromolar concentration. Computational modeling and in silico docking experiments suggested the possibility that nelfinavir may bind inside the S trimer structure, proximal to the S2 amino terminus directly inhibiting S-n and S-o-mediated membrane fusion. Also, it is possible that nelfinavir mesylate acts on cellular processes to inhibit S proteolytic processing. These results warrant further investigations of the potential of nelfinavir mesylate as an antiviral drug, especially at early times after SARS-CoV-2 symptoms appear.","rel_num_authors":6,"rel_authors":[{"author_name":"Farhana Musarrat","author_inst":"Louisiana State University"},{"author_name":"Vladimir Chouljenko","author_inst":"Louisiana State University"},{"author_name":"Rafiq Nabi","author_inst":"Louisiana State University"},{"author_name":"Achyut Dahai","author_inst":"University of Louisiana Monroe"},{"author_name":"Seetharama Jois","author_inst":"University of Louisiana Monroe"},{"author_name":"Konstantin Kousoulas","author_inst":"Louisiana State University"},{"author_name":"Martinus J.T. Blaauw","author_inst":"Bernhoven Hospital"},{"author_name":"Marc H.M. Thelen","author_inst":"Amphia Hospital"},{"author_name":"Marc G.L.M. Elisen","author_inst":"Elisabeth TweeSteden Hospital"},{"author_name":"Ron Kusters","author_inst":"Jeroen Bosch Ziekenhuis"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.04.21.20068858","rel_title":"SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors.","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.21.20068858","rel_abs":"It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their antibody response profile. Here, we performed a pilot study to assess the levels of anti-SARS-CoV-2 antibodies in samples taken from 491 pre- epidemic individuals, 51 patients from Hopital Bichat (Paris), 209 pauci-symptomatic individuals in the French Oise region and 200 contemporary Oise blood donors. Two in-house ELISA assays, that recognize the full-length nucleoprotein (N) or trimeric Spike (S) ectodomain were implemented. We also developed two novel assays: the S-Flow assay, which is based on the recognition of S at the cell surface by flow-cytometry, and the LIPS assay that recognizes diverse antigens (including S1 or N C- terminal domain) by immunoprecipitation. Overall, the results obtained with the four assays were similar, with differences in sensitivity that can be attributed to the technique and the antigen in use. High antibody titers were associated with neutralisation activity, assessed using infectious SARS-CoV- 2 or lentiviral-S pseudotypes. In hospitalized patients, seroconversion and neutralisation occurred on 5-14 days post symptom onset, confirming previous studies. Seropositivity was detected in 29% of pauci-symptomatic individuals within 15 days post-symptoms and 3 % of blood of healthy donors collected in the area of a cluster of COVID cases. Altogether, our assays allow for a broad evaluation of SARS-CoV2 seroprevalence and antibody profiling in different population subsets.","rel_num_authors":51,"rel_authors":[{"author_name":"Ludivine Grzelak","author_inst":"Institut Pasteur"},{"author_name":"Sarah Temmam","author_inst":"Institut Pasteur"},{"author_name":"Cyril Planchais","author_inst":"Institut Pasteur"},{"author_name":"Caroline Demeret","author_inst":"Institut Pasteur"},{"author_name":"Christele Huon","author_inst":"Institut Pasteur"},{"author_name":"Florence Guivel","author_inst":"Institut Pasteur"},{"author_name":"Isabelle Staropoli","author_inst":"Institut Pasteur"},{"author_name":"Maxime Chazal","author_inst":"Institut Pasteur"},{"author_name":"Jeremy Dufloo","author_inst":"Institut Pasteur"},{"author_name":"Delphine Planas","author_inst":"Institut Pasteur"},{"author_name":"Julian Buchrieser","author_inst":"Institut Pasteur"},{"author_name":"Maaran Michael Rajah","author_inst":"Institut Pasteur"},{"author_name":"Remy Robinot","author_inst":"Institut Pasteur"},{"author_name":"Francoise Porrot","author_inst":"Institut Pasteur"},{"author_name":"Melanie Albert","author_inst":"Institut Pasteur"},{"author_name":"Kuang-Yu Chen","author_inst":"Institut Pasteur"},{"author_name":"Bernadette Crescenzo","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.04.23.055756","rel_title":"Search for SARS-CoV-2 inhibitors in currently approved drugs to tackle COVID-19 pandemia","rel_date":"2020-04-24","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.04.23.055756","rel_abs":"Different treatments are currently used for clinical management of SARS-CoV-2 infection, but little is known about their efficacy yet. Here we present ongoing results to compare currently available drugs for a variety of diseases to find out if they counteract SARS-CoV-2-induced cytopathic effect in vitro. Our goal is to prioritize antiviral activity to provide a solid evidence-driven rationale for forthcoming clinical trials. Since the most effective antiviral approaches are usually based on combined therapies that tackle the viral life cycle at different stages, we are also testing combinations of drugs that may be critical to reduce the emergence of resistant viruses. We will provide results as soon as they become available, so data should be interpreted with caution, clearly understanding the limitations of the in vitro model, that may not always reflect what could happen in vivo. Thus, our goal is to test the most active antivirals identified in adequate animal models infected with SARS-CoV-2, to add more information about possible in vivo efficacy. In turn, successful antivirals could be tested in clinical trials as treatments for infected patients, but also as pre-exposure prophylaxis to avoid novel infections until an effective and safe vaccine is developed.","rel_num_authors":11,"rel_authors":[{"author_name":"Jordi Rodon","author_inst":"IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB),"},{"author_name":"Marc Noguera-Julian","author_inst":"IrsiCaixa AIDS Research Institute"},{"author_name":"Itziar Erkizia","author_inst":"IrsiCaixa AIDS Research Institute"},{"author_name":"Alfonso Valencia","author_inst":"Barcelona Supercomputing Center"},{"author_name":"V\u00edctor Guallar","author_inst":"Barcelona Supercomputing Center"},{"author_name":"Jorge Carrillo","author_inst":"IrsiCaixa AIDS Research Institute"},{"author_name":"Juli\u00e0 Blanco","author_inst":"IrsiCaixa AIDS Research Institute"},{"author_name":"Joaquim Segal\u00e9s","author_inst":"UAB, CReSA (IRTA-UAB)"},{"author_name":"Bonaventura Clotet","author_inst":"IrsiCaixa AIDS Research Institute"},{"author_name":"J\u00falia Vergara-Alert","author_inst":"IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB)"},{"author_name":"Nuria Izquierdo-Useros","author_inst":"AIDS Research Institute IrsiCaixa"},{"author_name":"Maaran Michael Rajah","author_inst":"Institut Pasteur"},{"author_name":"Remy Robinot","author_inst":"Institut Pasteur"},{"author_name":"Francoise Porrot","author_inst":"Institut Pasteur"},{"author_name":"Melanie Albert","author_inst":"Institut Pasteur"},{"author_name":"Kuang-Yu Chen","author_inst":"Institut Pasteur"},{"author_name":"Bernadette Crescenzo","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"confirmatory results","category":"microbiology"},{"rel_doi":"10.1101\/2020.04.20.20068056","rel_title":"Impact of anti-androgenic therapies on COVID-19: an observational study in male population from a COVID-19 regional centre of Lombardy (Italy)","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.20.20068056","rel_abs":"Importance: There are gender differences in vulnerability to the Coronavirus disease 2019 (COVID-19), with men experiencing more severe disease at any age. The use of anti-androgen drugs, like 5-alpha reductase inhibitors (5ARIs), could protect from severe pulmonary disease. Objective: To determine whether men who received 5ARIs for benign prostatic hyperplasia (BPH) have a lower risk of hospitalization for COVID-19. Design: This is a case-control study on patients hospitalized for COVID-19 (cases), matched to beneficiaries of the Lombardy Regional Health Service (controls). Setting: Data were collected by two high-volume COVID-19 regional centres of Lombardy (Italy) from 1st March to 24th April 2020. Participants: Consecutive patients positive for SARS-CoV-2 virus according to the WHO guidance, who required hospitalization. Exposure: BPH treatment with 5ARIs (finasteride\/dutasteride) in the last six months . Main Outcome(s) and Measure(s): The primary outcome was to compare the prevalence of male patients chronically exposed to 5ARIs, who required hospitalization for COVID-19, with the one of age-matched males in Lombardy. Results: Overall, 1,432 COVID-19 patients were included. Among the 943 males, 45 (4.77%) patients were exposed to chronic 5ARI therapy. COVID-19 patients aged >55 years under 5ARI treatment were significantly less than expected on the basis of the prevalence of 5ARI treatment among age-matched controls (5.57 vs. 8.14%; p=0.0083, 95%CI=0.75-3.97%). This disproportion was even higher for men aged >65 (7.14 vs. 12.31%; p=0.0001, 95%CI=2.83-6.97%). Eighteen 5ARIs-patients died; the mean age of men who died was higher than those who did not: 75.98{+\/-}9.29 vs. 64.78{+\/-}13.57 (p<0.001). Cox regression and multivariable models did not show any correlation between the exposure to 5ARIs and protection against ICU admission or death: HR=0.79 (95%CI=0.54-1.15; p=0.22) and OR=1.23 (95%CI=0.81-1.87; p=0.33), respectively. Conclusions and Relevance: In this case-control study the use of 5ARIs was less frequent among patients hospitalized for COVID-19 than among controls, suggesting that men exposed to 5ARIs might be less vulnerable to severe COVID-19. This observation further supports the idea to test in randomized clinical trials whether anti-androgen therapies can prevent the transition from paucisymptomatic SARS-CoV-2 infection to overt pulmonary disease.","rel_num_authors":13,"rel_authors":[{"author_name":"Massimo Lazzeri","author_inst":"IRCCS Istituto Clinico Humanitas"},{"author_name":"Stefano Duga","author_inst":"Humanitas University"},{"author_name":"Elena Azzolini","author_inst":"IRCCS Istituto Clinico Humanitas"},{"author_name":"Vittorio Fasulo","author_inst":"IRCCS Istituto Clinico Humanitas"},{"author_name":"Nicolo Buffi","author_inst":"Humanitas University"},{"author_name":"Alberto Saita","author_inst":"IRCCS Istituto Clinico Humanitas"},{"author_name":"- The Humanitas COVID-19 Task Force","author_inst":""},{"author_name":"- The Humanitas Gavazzeni COVID-19 Task Force","author_inst":""},{"author_name":"Rodolfo Hurle","author_inst":"IRCCS Istituto Clinico Humanitas"},{"author_name":"Alessandro Nobili","author_inst":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"},{"author_name":"Maurizio Cecconi","author_inst":"Humanitas University"},{"author_name":"Paolo Casale","author_inst":"IRCCS Istituto Clinico Humanitas"},{"author_name":"Rosanna Asselta","author_inst":"Humanitas University"},{"author_name":"Francoise Porrot","author_inst":"Institut Pasteur"},{"author_name":"Melanie Albert","author_inst":"Institut Pasteur"},{"author_name":"Kuang-Yu Chen","author_inst":"Institut Pasteur"},{"author_name":"Bernadette Crescenzo","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.04.24.060418","rel_title":"Treating Influenza and SARS-CoV-2 via mRNA-encoded Cas13a","rel_date":"2020-04-24","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.04.24.060418","rel_abs":"Here, Cas13a has been used to target and mitigate influenza virus A (IAV) and SARS-CoV-2 using a synthetic mRNA-based platform. CRISPR RNAs (crRNA) against PB1 and highly conserved regions of PB2 were screened in conjunction with mRNA-encoded Cas13a. Screens were designed such that only guides that decreased influenza RNA levels in a Cas13-mediated fashion, were valid. Cas13a mRNA and validated guides, delivered post-infection, simulating treatment, were tested in combination and across multiplicities of infection. Their function was also characterized over time. Similar screens were performed for guides against SARS-CoV-2, yielding multiple guides that significantly impacted cytopathic effect. Last, the approach was utilized in vivo, demonstrating the ability to degrade influenza RNA in a mouse model of infection, using polymer-formulated, nebulizer-based mRNA delivery. Our findings demonstrate the applicability of Cas13a in mitigating respiratory infections both in vitro and in a mouse model, paving the way for future therapeutic use.","rel_num_authors":15,"rel_authors":[{"author_name":"Emmeline L Blanchard","author_inst":"Georgia Institute of Technology and Emory University"},{"author_name":"Daryll Vanover","author_inst":"Georgia Institute of Technology"},{"author_name":"Swapnil Subhash Bawage","author_inst":"Georgia Institute of Technology"},{"author_name":"Pooja Munnilal Tiwari","author_inst":"Georgia Institute of Technology"},{"author_name":"Laura Rotolo","author_inst":"Georgia Institute of Technology"},{"author_name":"Jared Beyersdorf","author_inst":"Georgia Institute of Technology"},{"author_name":"Hannah E. Peck","author_inst":"Georgia Institute of Technology"},{"author_name":"Nicholas C Bruno","author_inst":"Georgia Institute of Technology"},{"author_name":"Robert Hincapie","author_inst":"Georgia Institute of Technology"},{"author_name":"M. G. Finn","author_inst":"Georgia Institute of Technology"},{"author_name":"Frank Michel","author_inst":"University of Georgia"},{"author_name":"Eric R. Lafontaine","author_inst":"University of Georgia"},{"author_name":"Robert J Hogan","author_inst":"University of Georgia"},{"author_name":"Chiara Zurla","author_inst":"Georgia Institute of Technology"},{"author_name":"Philip J Santangelo","author_inst":"Georgia Institute of Technology"},{"author_name":"Kuang-Yu Chen","author_inst":"Institut Pasteur"},{"author_name":"Bernadette Crescenzo","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_no","type":"new results","category":"bioengineering"},{"rel_doi":"10.1101\/2020.04.20.20067538","rel_title":"Modest effects of contact reduction measures on the reproduction number of SARS-CoV-2 in the most affected European countries and the US","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.20.20067538","rel_abs":"Population density, behaviour and cultural habits strongly influence the spread of pathogens. Consequently, key epidemiological parameters may vary from country to country. Many estimates of SARS-CoV-2 and COVID-19 strongly depend on testing frequency and case definitions. The fatal cases due to SARS-CoV2 could be a more reliable parameter, since missing of deaths is less likely. We analysed the dynamics of new infection and death cases to estimate the daily reproduction numbers (Rt) and the effectiveness of control measures in the most affected European Countries and the US. In summary, calculating Rt based on the daily number of deaths as well as of new infections may lead to more reliable estimates than those based on infection cases alone, as death based Rt are expected to be less susceptible to testing bias or limited capacities.","rel_num_authors":3,"rel_authors":[{"author_name":"Armin Ensser","author_inst":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universitaet Erlangen-Nuernberg (FAU)"},{"author_name":"Pia \u00dcberla","author_inst":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universitaet Erlangen-Nuernberg (FAU)"},{"author_name":"Klaus \u00dcberla","author_inst":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universitaet Erlangen-Nuernberg (FAU)"},{"author_name":"Pooja Munnilal Tiwari","author_inst":"Georgia Institute of Technology"},{"author_name":"Laura Rotolo","author_inst":"Georgia Institute of Technology"},{"author_name":"Jared Beyersdorf","author_inst":"Georgia Institute of Technology"},{"author_name":"Hannah E. Peck","author_inst":"Georgia Institute of Technology"},{"author_name":"Nicholas C Bruno","author_inst":"Georgia Institute of Technology"},{"author_name":"Robert Hincapie","author_inst":"Georgia Institute of Technology"},{"author_name":"M. G. Finn","author_inst":"Georgia Institute of Technology"},{"author_name":"Frank Michel","author_inst":"University of Georgia"},{"author_name":"Eric R. Lafontaine","author_inst":"University of Georgia"},{"author_name":"Robert J Hogan","author_inst":"University of Georgia"},{"author_name":"Chiara Zurla","author_inst":"Georgia Institute of Technology"},{"author_name":"Philip J Santangelo","author_inst":"Georgia Institute of Technology"},{"author_name":"Kuang-Yu Chen","author_inst":"Institut Pasteur"},{"author_name":"Bernadette Crescenzo","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.04.24.059576","rel_title":"Introductions and early spread of SARS-CoV-2 in France","rel_date":"2020-04-24","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.04.24.059576","rel_abs":"Following the emergence of coronavirus disease (COVID-19) in Wuhan, China in December 2019, specific COVID-19 surveillance was launched in France on January 10, 2020. Two weeks later, the first three imported cases of COVID-19 into Europe were diagnosed in France. We sequenced 97 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes from samples collected between January 24 and March 24, 2020 from infected patients in France. Phylogenetic analysis identified several early independent SARS-CoV-2 introductions without local transmission, highlighting the efficacy of the measures taken to prevent virus spread from symptomatic cases. In parallel, our genomic data reveals the later predominant circulation of a major clade in many French regions, and implies local circulation of the virus in undocumented infections prior to the wave of COVID-19 cases. This study emphasizes the importance of continuous and geographically broad genomic sequencing and calls for further efforts with inclusion of asymptomatic infections.","rel_num_authors":14,"rel_authors":[{"author_name":"Fabiana Gambaro","author_inst":"Institut Pasteur"},{"author_name":"Artem Baidaliuk","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Melanie Albert","author_inst":"Institut Pasteur"},{"author_name":"Andreea Alexandru","author_inst":"Institut Pasteur"},{"author_name":"Maud Vanpeene","author_inst":"Institut Pasteur"},{"author_name":"Meline Bizard","author_inst":"Institut Pasteur"},{"author_name":"Angela Brisebarre","author_inst":"Institut Pasteur"},{"author_name":"Marion Barbet","author_inst":"Institut Pasteur"},{"author_name":"Fawzi Derrar","author_inst":"Institut Pasteur of Algiers"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Etienne Simon-Loriere","author_inst":"Institut Pasteur"},{"author_name":"Philip J Santangelo","author_inst":"Georgia Institute of Technology"},{"author_name":"Kuang-Yu Chen","author_inst":"Institut Pasteur"},{"author_name":"Bernadette Crescenzo","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"genomics"},{"rel_doi":"10.1101\/2020.04.20.20064899","rel_title":"Epidemiological characteristics of COVID-19 in medical staff members of neurosurgery departments in Hubei province: A multicentre descriptive study","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.20.20064899","rel_abs":"Background The novel coronavirus (SARS-CoV-2) has infected a large number of healthcare workers in Hubei province, China. In addition to infectious and respiratory disease physicians, many doctors in other medical fields have been infected. Methods We prospectively collected epidemiological data on medical staff members who are working in neurosurgery departments in 107 hospitals in Hubei province through self-reported questionnaires or telephone interviews. Data of medical staff members with laboratory-confirmed coronavirus disease 2019 (COVID-19) were analysed. The final follow-up date was 1 March 2020. Findings A total of 5,442 neurosurgery department medical staff members were surveyed. One hundred and twenty cases, involving 54 doctors and 66 nurses, were found to have been infected with SARS-CoV-2. The overall incidence was 2.2%. These cases were concentrated in 26 centres, 16 of which had admitted a total of 59 patients with COVID-19 complicated by craniocerebral disease. Medical staff members in centres receiving COVID-19 patients had a higher risk of contracting infection than those in centres not receiving COVID-19 patients (relative risk: 19.6; 95% confidence interval: 12.6-30.6). Contact with either COVID-19 patients (62.5%, 75\/120) or infected colleagues (30.8%, 37\/120) was the most common mode of transmission. About 78.3% (94\/120) of the infected cases wore surgical masks, whereas 20.8% (25\/120) failed to use protection when exposed to the source of infection. Severe infections were observed in 11.7% (14\/120) of the cases, with one death (0.8%, 1\/120). All the infected medical staff members had been discharged from the hospital. A total of 1,287 medical staff members were dispatched to participate in the frontline response to COVID-19 under level 2 protection of whom one was infected. Medical staff members who took inadequate protection had a higher risk of contracting infection than those using level 2 protection (relative risk: 36.9; 95% confidence interval: 5.2-263.6). Interpretation Neurosurgical staff members in Hubei province were seriously affected by COVID-19. Level 2 protection and strengthening of protective measures are likely to be effective in preventing medical workers from being infected.","rel_num_authors":12,"rel_authors":[{"author_name":"Qiangping Wang","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022"},{"author_name":"Xing Huang","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Yansen Bai","author_inst":"Department of Occupational and Environmental Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong"},{"author_name":"Xuan Wang","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Haijun Wang","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Xuebin Hu","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Feng Wang","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Xianke Wang","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Jincao Chen","author_inst":"Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan, China, 430071."},{"author_name":"Qianxue Chen","author_inst":"Department of Neurosurgery, Hubei Provincial People's Hospital of Wuhan University, Wuhan, China, 430060."},{"author_name":"Xiaobing Jiang Sr.","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Hongyang Zhao","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Etienne Simon-Loriere","author_inst":"Institut Pasteur"},{"author_name":"Philip J Santangelo","author_inst":"Georgia Institute of Technology"},{"author_name":"Kuang-Yu Chen","author_inst":"Institut Pasteur"},{"author_name":"Bernadette Crescenzo","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.04.24.059667","rel_title":"Critical role of type III interferon in controlling SARS-CoV-2 infection, replication and spread in primary human intestinal epithelial cells","rel_date":"2020-04-24","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.04.24.059667","rel_abs":"SARS-CoV-2 is an unprecedented worldwide health problem that requires concerted and global approaches to better understand the virus in order to develop novel therapeutic approaches to stop the COVID-19 pandemic and to better prepare against potential future emergence of novel pandemic viruses. Although SARS-CoV-2 primarily targets cells of the lung epithelium causing respiratory infection and pathologies, there is growing evidence that the intestinal epithelium is also infected. However, the importance of the enteric phase of SARS-CoV-2 for virus-induced pathologies, spreading and prognosis remains unknown. Here, using both colon-derived cell lines and primary non-transformed colon organoids, we engage in the first comprehensive analysis of SARS-CoV-2 lifecycle in human intestinal epithelial cells. Our results demonstrate that human intestinal epithelial cells fully support SARS-CoV-2 infection, replication and production of infectious de-novo virus particles. Importantly, we identified intestinal epithelial cells as the best culture model to propagate SARS-CoV-2. We found that viral infection elicited an extremely robust intrinsic immune response where, interestingly, type III interferon mediated response was significantly more efficient at controlling SARS-CoV-2 replication and spread compared to type I interferon. Taken together, our data demonstrate that human intestinal epithelial cells are a productive site of SARS-CoV-2 replication and suggest that the enteric phase of SARS-CoV-2 may participate in the pathologies observed in COVID-19 patients by contributing in increasing patient viremia and by fueling an exacerbated cytokine response.","rel_num_authors":9,"rel_authors":[{"author_name":"Megan Lynn Stanifer","author_inst":"Heidelberg University Hospital, Germany"},{"author_name":"Carmon Kee","author_inst":"DKFZ, Heidelberg, Germany"},{"author_name":"Mirko Cortese","author_inst":"Department of Infectious Diseases,  Heidelberg University, Germany"},{"author_name":"Sergio triana","author_inst":"EMBL, Heidelberg"},{"author_name":"Markus Mukenhirn","author_inst":"Department of Infectious Diseases,  Heidelberg University, Germany"},{"author_name":"Hans-Georg Kraeusslich","author_inst":"Department of Infectious Diseases,  Heidelberg University, Germany"},{"author_name":"Theodore Alexandrov","author_inst":"EMBL"},{"author_name":"Ralf Bartenschlager","author_inst":"Department of Infectious Diseases,  Heidelberg University, Germany"},{"author_name":"Steeve Boulant","author_inst":"University Hospital Heidelberg"},{"author_name":"Qianxue Chen","author_inst":"Department of Neurosurgery, Hubei Provincial People's Hospital of Wuhan University, Wuhan, China, 430060."},{"author_name":"Xiaobing Jiang Sr.","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Hongyang Zhao","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Etienne Simon-Loriere","author_inst":"Institut Pasteur"},{"author_name":"Philip J Santangelo","author_inst":"Georgia Institute of Technology"},{"author_name":"Kuang-Yu Chen","author_inst":"Institut Pasteur"},{"author_name":"Bernadette Crescenzo","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_no","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.04.19.20062174","rel_title":"Higher mortality in men from COVID19 infection-understanding the factors that drive the differences between the biological sexes.","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.19.20062174","rel_abs":"The emergent global pandemic caused by the rapid spread of Severe Acute Respiratory syndrome- Coronavirus-2 (SARS-CoV-2) has led to increased mortality and negatively impacted day to day activities of humankind within a short period of time. As the data is rapidly emerging from earlier outbreak locations around the world, there are efforts to assimilate this with the knowledge from prior epidemics and find rapid solutions for this. One of the observations and a recurring theme is the disproportionate differences in the incidence of infection and the consequent mortality between males and females. We, therefore, analyzed retrospective datasets from the previous epidemics and the ongoing pandemic in order to address these differences in clinical outcomes. The data shows that even though the infection rates are similar, the odds ratio of male mortality remains high, indicating a divergence in the crosstalk between the three pathogenic human Coronavirus (hCoVs)- the SARS-CoV, MERS-CoV and the SARS-CoV-2 and immune effectors in the two sexes. One proximate cause is the sex-specific modulation of the X-linked genes that can influence susceptibility to infection. Future studies are needed to confirm these findings, which can form the basis for developing rational strategies for ending the current and preventing future pandemics.","rel_num_authors":7,"rel_authors":[{"author_name":"Swaminathan P Iyer","author_inst":"University of Texas MD Anderson Cancer Center"},{"author_name":"Joe Ensor","author_inst":"Houston Methodist Research Institute"},{"author_name":"Kartik Anand","author_inst":"Great Plains Health"},{"author_name":"Patrick Hwu","author_inst":"University of Texas MD Anderson Cancer Center"},{"author_name":"Vivek Subbiah","author_inst":"University of Texas MD Anderson Cancer Center"},{"author_name":"Christopher Flowers","author_inst":"University of Texas MD Anderson Cancer Center"},{"author_name":"Rudragouda Channappanavar","author_inst":"University of Tennessee Health Science Center"},{"author_name":"Ralf Bartenschlager","author_inst":"Department of Infectious Diseases,  Heidelberg University, Germany"},{"author_name":"Steeve Boulant","author_inst":"University Hospital Heidelberg"},{"author_name":"Qianxue Chen","author_inst":"Department of Neurosurgery, Hubei Provincial People's Hospital of Wuhan University, Wuhan, China, 430060."},{"author_name":"Xiaobing Jiang Sr.","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Hongyang Zhao","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Etienne Simon-Loriere","author_inst":"Institut Pasteur"},{"author_name":"Philip J Santangelo","author_inst":"Georgia Institute of Technology"},{"author_name":"Kuang-Yu Chen","author_inst":"Institut Pasteur"},{"author_name":"Bernadette Crescenzo","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.04.22.055863","rel_title":"Genomic, geographic and temporal distributions of SARS-CoV-2 mutations","rel_date":"2020-04-24","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.04.22.055863","rel_abs":"The COVID-19 pandemic is the most significant public health issue in recent history. Its causal agent, SARS-CoV-2, has evolved rapidly since its first emergence in December 2019. Mutations in the viral genome have critical impacts on the adaptation of viral strains to the local environment, and may alter the characteristics of viral transmission, disease manifestation, and the efficacy of treatment and vaccination. Using the complete sequences of 1,932 SARS-CoV-2 genomes, we examined the genomic, geographic and temporal distributions of aged, new, and frequent mutations of SARS-CoV-2, and identified six phylogenetic clusters of the strains, which also exhibit a geographic preference in different continents. Mutations in the form of single nucleotide variations (SNVs) provide a direct interpretation for the six phylogenetic clusters. Linkage disequilibrium, haplotype structure, evolutionary process, global distribution of mutations unveiled a sketch of the mutational history. Additionally, we found a positive correlation between the average mutation count and case fatality, and this correlation had strengthened with time, suggesting an important role of SNVs on disease outcomes. This study suggests that SNVs may become an important consideration in virus detection, clinical treatment, drug design, and vaccine development to avoid target shifting, and that continued isolation and sequencing is a crucial component in the fight against this pandemic.\n\nSignificance StatementMutation is the driving force of evolution for viruses like SARS-CoV-2, the causal agent of COVID-19. In this study, we discovered that the genome of SARS-CoV-2 is changing rapidly from the originally isolated form. These mutations have been spreading around the world and caused more than 2.5 million of infected cases and 170 thousands of deaths. We found that fourteen frequent mutations identified in this study can characterize the six main clusters of SARS-CoV-2 strains. In addition, we found the mutation burden is positively correlated with the fatality of COVID-19 patients. Understanding mutations in the SARS-CoV-2 genome will provide useful insight for the design of treatment and vaccination.","rel_num_authors":9,"rel_authors":[{"author_name":"Hsin-Chou Yang","author_inst":"Institute of Statistical Science, Academia Sinica"},{"author_name":"Chun-houh Chen","author_inst":"Institute of Statistical Science, Academia Sinica"},{"author_name":"Jen-Hung Wang","author_inst":"Institute of Statistical Science, Academia Sinica"},{"author_name":"Hsiao-Ch Liao","author_inst":"Institute of Statistical Science, Academia Sinica"},{"author_name":"Chih-Ting Yang","author_inst":"Institute of Statistical Science, Academia Sinica"},{"author_name":"Chia-Wei Chen","author_inst":"Institute of Statistical Science, Academia Sinica"},{"author_name":"Yin-Chun Lin","author_inst":"Institute of Statistical Science, Academia Sinica"},{"author_name":"Chiun-How Kao","author_inst":"Institute of Statistical Science, Academia Sinica"},{"author_name":"James C. Liao","author_inst":"Institute of Biological Chemistry, Academia Sinica"},{"author_name":"Qianxue Chen","author_inst":"Department of Neurosurgery, Hubei Provincial People's Hospital of Wuhan University, Wuhan, China, 430060."},{"author_name":"Xiaobing Jiang Sr.","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Hongyang Zhao","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Etienne Simon-Loriere","author_inst":"Institut Pasteur"},{"author_name":"Philip J Santangelo","author_inst":"Georgia Institute of Technology"},{"author_name":"Kuang-Yu Chen","author_inst":"Institut Pasteur"},{"author_name":"Bernadette Crescenzo","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.04.24.058933","rel_title":"Evolution and molecular characteristics of SARS-CoV-2 genome","rel_date":"2020-04-24","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.04.24.058933","rel_abs":"ObjectivesTo reveal epidemic trend and possible origins of SARS-CoV-2 by exploring its evolution and molecular characteristics based on a large number of genomes since it has infected millions of people and spread quickly all over the world.\n\nMethodsVarious evolution analysis methods were employed.\n\nResultsThe estimated Ka\/Ks ratio of SARS-CoV-2 is 1.008 or 1.094 based on 622 or 3624 SARS-CoV-2 genomes, and the time to the most recent common ancestor (tMRCA) was inferred in late September 2019. Further 9 key specific sites of highly linkage and four major haplotypes H1, H2, H3 and H4 were found. The Ka\/Ks, detected population size and development trends of each major haplotype showed H3 and H4 subgroups were going through a purify evolution and almost disappeared after detection, indicating H3 and H4 might have existed for a long time, while H1 and H2 subgroups were going through a near neutral or neutral evolution and globally increased with time. Notably the frequency of H1 was generally high in Europe and correlated to death rate (r>0.37).\n\nConclusionsIn this study, the evolution and molecular characteristics of more than 16000 genomic sequences provided a new perspective for revealing epidemiology of SARS-CoV-2.","rel_num_authors":10,"rel_authors":[{"author_name":"Yunmeng Bai","author_inst":"South China University of Technology"},{"author_name":"Dawei Jiang","author_inst":"South China University of Technology"},{"author_name":"Jerome R Lon","author_inst":"South China University of Technology"},{"author_name":"Xiaoshi Chen","author_inst":"South China University of Technology"},{"author_name":"Meiling Hu","author_inst":"South China University of Technology"},{"author_name":"Shudai Lin","author_inst":"South China University of Technology"},{"author_name":"Zixi Chen","author_inst":"South China University of Technology"},{"author_name":"Xiaoning Wang","author_inst":"State Clinic Center of Gearitic, Chinese PLA General Hospital"},{"author_name":"Yuhuan Meng","author_inst":"Guangzhou KingMed Transformative Medicine Institute Co., Ltd"},{"author_name":"Hongli Du","author_inst":"South China University of Technology"},{"author_name":"Xiaobing Jiang Sr.","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Hongyang Zhao","author_inst":"Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 430022."},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Etienne Simon-Loriere","author_inst":"Institut Pasteur"},{"author_name":"Philip J Santangelo","author_inst":"Georgia Institute of Technology"},{"author_name":"Kuang-Yu Chen","author_inst":"Institut Pasteur"},{"author_name":"Bernadette Crescenzo","author_inst":"Institut Pasteur"},{"author_name":"Flora Donati","author_inst":"Institut Pasteur"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_no","type":"new results","category":"bioinformatics"},{"rel_doi":"10.1101\/2020.04.24.057323","rel_title":"Validation of a SARS-CoV-2 spike ELISA for use in contact investigations and serosurveillance","rel_date":"2020-04-24","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.04.24.057323","rel_abs":"Since emergence of SARS-CoV-2 in late 2019, there has been a critical need to understand prevalence, transmission patterns, to calculate the burden of disease and case fatality rates. Molecular diagnostics, the gold standard for identifying viremic cases, are not ideal for determining true case counts and rates of asymptomatic infection. Serological detection of SARS-CoV-2 specific antibodies can contribute to filling these knowledge gaps. In this study, we describe optimization and validation of a SARS-CoV-2-specific-enzyme linked immunosorbent assay (ELISA) using the prefusion-stabilized form of the spike protein [1]. We performed receiver operator characteristic (ROC) analyses to define the specificities and sensitivities of the optimized assay and examined cross reactivity with immune sera from persons confirmed to have had infections with other coronaviruses. These assays will be used to perform contact investigations and to conduct large-scale, cross sectional surveillance to define disease burden in the population.","rel_num_authors":18,"rel_authors":[{"author_name":"Brandi Freeman","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Sandra Lester","author_inst":"Synergy America Inc."},{"author_name":"Lisa Mills","author_inst":"Eagle Global Scientific"},{"author_name":"Mohammad Ata Ur Rasheed","author_inst":"Synergy America Inc."},{"author_name":"Stefany Moye","author_inst":"Eagle Global Scientific"},{"author_name":"Olubukola Abiona","author_inst":"National Institutes of Health"},{"author_name":"Geoffrey Hutchinson","author_inst":"National Institutes of Health"},{"author_name":"Maria Morales-Betoulle","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Inna Krapinunaya","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Ardith Gibbons","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Cheng-Feng Chiang","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Deborah Cannon","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"John Klena","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Jeffrey A. Johnson","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Sherry Michelle Owen","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Barney S. Graham","author_inst":"National Institute of Health"},{"author_name":"Kizzmekia S. Corbett","author_inst":"National Institutes of Health"},{"author_name":"Natalie J. Thornburg","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc0","type":"new results","category":"immunology"},{"rel_doi":"10.1101\/2020.04.23.057042","rel_title":"ACE2 polymorphisms and individual susceptibility to SARS-CoV-2 infection: insights from an in silico study","rel_date":"2020-04-24","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.04.23.057042","rel_abs":"The current SARS covid-19 epidemic spread appears to be influenced by ethnical, geographical and sex-related factors that may involve genetic susceptibility to diseases. Similar to SARS-CoV, SARS-CoV-2 exploits angiotensin-converting enzyme 2 (ACE2) as a receptor to invade cells, notably type II alveolar epithelial cells. Importantly, ACE2 gene is highly polymorphic. Here we have used in silico tools to analyze the possible impact of ACE2 single-nucleotide polymorphisms (SNPs) on the interaction with SARS-CoV-2 spike glycoprotein. We found that S19P (common in African people) and K26R (common in European people) were, among the most diffused SNPs worldwide, the only two SNPs that were able to potentially affect the interaction of ACE2 with SARS-CoV-2 spike. FireDock simulations demonstrated that while S19P may decrease, K26R might increase the ACE2 affinity for SARS-CoV-2 Spike. This finding suggests that the S19P may genetically protect, and K26R may predispose to more severe SARS-CoV-2 disease.","rel_num_authors":6,"rel_authors":[{"author_name":"Matteo Calcagnile","author_inst":"Salento University, Italy"},{"author_name":"Patricia Forgez","author_inst":"INSERM, France"},{"author_name":"Antonio Iannelli","author_inst":"CHU Nice, France"},{"author_name":"Cecilia Bucci","author_inst":"Salento University, Italy"},{"author_name":"Marco Alifano","author_inst":"Cochin Hospital APHP University of Paris"},{"author_name":"Pietro Alifano","author_inst":"Salento University, Italy"},{"author_name":"Geoffrey Hutchinson","author_inst":"National Institutes of Health"},{"author_name":"Maria Morales-Betoulle","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Inna Krapinunaya","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Ardith Gibbons","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Cheng-Feng Chiang","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Deborah Cannon","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"John Klena","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Jeffrey A. Johnson","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Sherry Michelle Owen","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Barney S. Graham","author_inst":"National Institute of Health"},{"author_name":"Kizzmekia S. Corbett","author_inst":"National Institutes of Health"},{"author_name":"Natalie J. Thornburg","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.04.24.050534","rel_title":"ACE2 Homo-dimerization, Human Genomic variants and Interaction of Host Proteins Explain High Population Specific Differences in Outcomes of COVID19","rel_date":"2020-04-24","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.04.24.050534","rel_abs":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive single-stranded RNA virus that causes a highly contagious Corona Virus Disease (COVID19). Entry of SARS-CoV-2 in human cells depends on binding of the viral spike (S) proteins to cellular receptor Angiotensin-converting enzyme 2 (ACE2) and on S-protein priming by host cell serine protease TMPRSS2. Recently, COVID19 has been declared pandemic by World Health Organization (WHO) yet high differences in disease outcomes across countries have been seen. We provide evidences to explain these population-level differences. One of the key factors of entry of the virus in host cells presumably is because of differential interaction of viral proteins with host cell proteins due to different genetic backgrounds. Based on our findings, we conclude that a higher expression of ACE2 is facilitated by natural variations, acting as Expression quantitative trait loci (eQTLs), with different frequencies in different populations. We suggest that high expression of ACE2 results in homo-dimerization, proving disadvantageous for TMPRSS2 mediated cleavage of ACE2; whereas, the monomeric ACE2 has higher preferential binding with SARS-CoV-2 S-Protein vis-a-vis its dimerized counterpart. Further, eQTLs in TMPRSS2 and natural structural variations in the gene may also result in differential outcomes towards priming of viral S-protein, a critical step for entry of the Virus in host cells. In addition, we suggest that several key host genes, like SLC6A19, ADAM17, RPS6, HNRNPA1, SUMO1, NACA, BTF3 and some other proteases as Cathepsins, might have a critical role. To conclude, understanding population specific differences in these genes may help in developing appropriate management strategies for COVID19 with better therapeutic interventions.","rel_num_authors":6,"rel_authors":[{"author_name":"Swarkar Sharma","author_inst":"Human Genetics Research Group, School of Biotechnology, Shri Mata Vaishno Devi University, Katra, Jammu and Kashmir, India"},{"author_name":"Inderpal Singh","author_inst":"Independent Researcher, Bioinfores Pvt. Ltd., R. S. Pura, Jammu, Jammu and Kashmir, India"},{"author_name":"Shazia Haider","author_inst":"Jaypee Institute of Information Technology, Noida, sector-62, Uttar Pradesh, India"},{"author_name":"Md. Zubbair Malik","author_inst":"Jawaharlal Nehru University, New Delhi, India"},{"author_name":"Kalaiarasan Ponnusamy","author_inst":"School of Biotechnology, Jawaharlal Nehru University, New Delhi, India"},{"author_name":"Ekta Rai","author_inst":"Human Genetics Research Group, School of Biotechnology, Shri Mata Vaishno Devi University, Katra, Jammu and Kashmir, India"},{"author_name":"Geoffrey Hutchinson","author_inst":"National Institutes of Health"},{"author_name":"Maria Morales-Betoulle","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Inna Krapinunaya","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Ardith Gibbons","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Cheng-Feng Chiang","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Deborah Cannon","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"John Klena","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Jeffrey A. Johnson","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Sherry Michelle Owen","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Barney S. Graham","author_inst":"National Institute of Health"},{"author_name":"Kizzmekia S. Corbett","author_inst":"National Institutes of Health"},{"author_name":"Natalie J. Thornburg","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_no","type":"new results","category":"genetics"},{"rel_doi":"10.1101\/2020.04.20.20065953","rel_title":"The production of antibodies for SARS-CoV-2 and its clinical implication","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.20.20065953","rel_abs":"Background: Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), a novel betacoronavirus, has caused an outburst of pneumonia cases in Wuhan, China. We report the production of specific IgM and IgG antibodies after the infection of SARS-CoV-2 and its implication for the diagnosis, pathology and the course of the disease as well as the recurrence of positive nucleic acid tests after discharge. Methods: Test results for SARS-CoV-2 IgM and IgG antibodies of 221 confirmed COVID-19 patients were retrospectively examined, and their clinical data were collected and analyzed based on various subgroups. SARS-CoV-2 IgM and IgG antibodies were determined with the chemiluminescence method. Findings: The concentration (S\/CO) of SARS-CoV-2 IgM and IgG antibodies peaked on day 19-21 after symptom onset, with a median of 17.38 (IQR 4.39-36.4) for IgM and 5.59 (IQR 0.73-13.65) for IgG. Detection rates reached highest on day 16-18 and day 19-21 for IgM and IgG, which were 73.6% and 98.6%, respectively, with significantly higher concentration of IgG in critically ill patients than in those with mild to moderate disease (P=0.027). The concentration of the antibodies on day 16-21 is not correlated with the course or outcome of the disease (Spearman r < 0.20, P > 0.05). Nasopharyngeal swabs revealed positive SARS-CoV-2 RNA in up to 52.7% of recovered patients after discharge, whose IgG proved to be significantly lower than that of those with negative RNA results (P = 0.009). IgG and IgM were tested twice within 14 days after discharge with a 7-day interval, and the second testing of these antibodies displayed a decrease in concentration of 21.2% (IQR, 11.2%34.48%) for IgG and 23.05% (IQR, -27.96%46.13%) for IgM, without statistical significance between the patients with re-detectable positive RNA results and those with negative RNA results after discharge. However, those with positive results experienced a count decrease in lymphocyte subsets. Interpretation: The concentration of SARS-CoV-2 IgM and IgG antibodies peaked on day 19-21 after symptom onset, and antibody testing on day 16-21 is associated with increased detection rates, but the antibody concentration does not affect the course and outcome of the infection. Recovering patients with re-detectable positive SARS-CoV-2 RNA displayed lower concentration of IgG, but the downward trend of IgG during recovery indicated its limited duration of protection, and the protective effect of IgG remains to be investigated.","rel_num_authors":14,"rel_authors":[{"author_name":"Qianfang Hu","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Xiaoping Cui","author_inst":"Department of Medical Laboratory, Chongqing Three Gorges Central Hospital"},{"author_name":"Xinzhu Liu","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Bin Peng","author_inst":"Department of Health Statistics, School of Public Health and Management, Chongqing Medical University"},{"author_name":"Jinyue Jiang","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Xiaohui Wang","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Yan Li","author_inst":"Department of Health Management Centre, Chongqing Three Gorges Central Hospital,"},{"author_name":"Wenhui Hu","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Zhi Ao","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Jun Duan","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Xue Wang","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Linxiao Zhu","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Shuliang Guo","author_inst":"the First Affiliated Hospital of Chongqing Medical University, Chongqing, China"},{"author_name":"Guicheng Wu","author_inst":"Department of Hepatopathy, Chongqing Three Gorges Central Hospital"},{"author_name":"Sherry Michelle Owen","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Barney S. Graham","author_inst":"National Institute of Health"},{"author_name":"Kizzmekia S. Corbett","author_inst":"National Institutes of Health"},{"author_name":"Natalie J. Thornburg","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"allergy and immunology"},{"rel_doi":"10.1101\/2020.04.21.20066761","rel_title":"Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.21.20066761","rel_abs":"The risk-benefit ratio associated with the use of repurposed drugs to treat 2019 SARS-CoV-2 related infectious disease (COVID-19) is complicated since benefits are awaited, not proven. A thorough literature search was conducted to source information on the pharmacological properties of 5 drugs and 1 combination (azithromycin, chloroquine, favipiravir, hydroxychloroquine, remdesivir, and lopinavir\/ritonavir) repurposed to treat COVID-19. A risk assessment of drug-induced Long QT Syndrome (LQTS) associated with COVID-19 repurposed drugs was performed and compared to 23 well-known torsadogenic and 10 low torsadogenic risk compounds. Computer calculations were performed using pharmacokinetic and pharmacodynamic data, including affinity to block the rapid component of the delayed rectifier cardiac potassium current (IKr) encoded by the human ether-a-go-go gene (hERG), propensity to prolong cardiac repolarization (QT interval) and cause torsade de pointes (TdP). Seven different LQTS indices were calculated and compared. The U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried with specific key words relating to arrhythmogenic events. Estimators of LQTS risk levels indicated a very high or moderate risk for all COVID-19 repurposed drugs with the exception for azithromycin, although cases of TdP have been reported with this drug. There was excellent agreement among the various indices used to assess risk of drug-induced LQTS for the 6 repurposed medications and 23 torsadogenic compounds. Based on our results, monitoring of the QT interval shall be performed when some COVID-19 repurposed drugs are used, as such monitoring is possible for hospitalized patients or with the use of biodevices for outpatients.","rel_num_authors":7,"rel_authors":[{"author_name":"Veronique Michaud","author_inst":"Tabula Rasa HealthCare"},{"author_name":"Pamela Dow","author_inst":"Tabula Rasa HealthCare"},{"author_name":"Sweilem B Al Rihani","author_inst":"Tabula Rasa HealthCare"},{"author_name":"Malavika Deodhar","author_inst":"Tabula Rasa HealthCare"},{"author_name":"Meghan Arwood","author_inst":"Tabula Rasa HealthCare"},{"author_name":"Brian Cicali","author_inst":"University of Florida"},{"author_name":"Jacques Turgeon","author_inst":"Tabula Rasa HealthCare"},{"author_name":"Wenhui Hu","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Zhi Ao","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Jun Duan","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Xue Wang","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Linxiao Zhu","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Shuliang Guo","author_inst":"the First Affiliated Hospital of Chongqing Medical University, Chongqing, China"},{"author_name":"Guicheng Wu","author_inst":"Department of Hepatopathy, Chongqing Three Gorges Central Hospital"},{"author_name":"Sherry Michelle Owen","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Barney S. Graham","author_inst":"National Institute of Health"},{"author_name":"Kizzmekia S. Corbett","author_inst":"National Institutes of Health"},{"author_name":"Natalie J. Thornburg","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"pharmacology and therapeutics"},{"rel_doi":"10.1101\/2020.04.20.20068676","rel_title":"Understanding the Collective Responses of Populations to the COVID-19 Pandemic in Mainland China","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.20.20068676","rel_abs":"Timely information acquisition and stay-at-home measures have been considered as two effective steps that every person could take to help contain the coronavirus (COVID-19) pandemic. From the perspectives of information and mobility, this work aims at evaluating to what degree the massive population has responded to the emergencies of the COVID- 19 pandemic in China. Using the real-time and historical data collected from the Baidu Maps and Baidu search engines, we confirm the strong correlation between the local pandemic situation in every major Chinese city and the population inflows from Wuhan between 1 January and 23 January 2020. We further evidence that, in cities under more critical situations, people are likely to engage COVID-19-related searches more frequently, while they are not likely to escape from the cities. Finally, the correlation analysis using search and mobility data shows that well-informed individuals are likely to travel less, even while the overall travel demands are low compared to the historical records. Partial correlation analysis has been conducted to test the significance of these observations with respect to other controlling factors.","rel_num_authors":9,"rel_authors":[{"author_name":"Haoyi Xiong","author_inst":"Baidu Inc."},{"author_name":"Ji Liu","author_inst":"Baidu Inc."},{"author_name":"Jizhou Huang","author_inst":"Baidu Inc."},{"author_name":"Siyu Huang","author_inst":"Baidu Inc."},{"author_name":"Haozhe An","author_inst":"Baidu Inc."},{"author_name":"Qi Kang","author_inst":"Baidu Inc."},{"author_name":"Ying Li","author_inst":"Baidu Inc."},{"author_name":"Dejing Dou","author_inst":"Baidu Inc."},{"author_name":"Haifeng Wang","author_inst":"Baidu Inc."},{"author_name":"Jun Duan","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Xue Wang","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Linxiao Zhu","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Shuliang Guo","author_inst":"the First Affiliated Hospital of Chongqing Medical University, Chongqing, China"},{"author_name":"Guicheng Wu","author_inst":"Department of Hepatopathy, Chongqing Three Gorges Central Hospital"},{"author_name":"Sherry Michelle Owen","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Barney S. Graham","author_inst":"National Institute of Health"},{"author_name":"Kizzmekia S. Corbett","author_inst":"National Institutes of Health"},{"author_name":"Natalie J. Thornburg","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.04.21.20074468","rel_title":"Covid-19 and Inequity: A comparative spatial analysis of New York City and Chicago hot spots","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.21.20074468","rel_abs":"There have been numerous reports that the impact of the ongoing COVID-19 epidemic has disproportionately impacted traditionally vulnerable communities, including well-researched social determinants of health, such as racial and ethnic minorities, migrants, and the economically challenged. The goal of this ecological cross-sectional study is to examine the demographic and economic nature of spatial hot and cold spots of SARS-CoV-2 rates in New York City and Chicago as of April 13, 2020. In both cities, cold spots (clusters of low SARS-CoV-2 rate ZIP code tabulation areas) demonstrated typical protective factors associated with the social determinants of health and the ability to social distance. These neighborhoods tended to be wealthier, have higher educational attainment, higher proportions of non-Hispanic white residents, and more workers in managerial occupations. Hot spots (clusters of high SARS-CoV-2 rate ZIP code tabulation areas) also had similarities, such as lower rates of college graduates and higher proportions of people of color. It also appears to be larger households (more people per household), rather than overall population density, that may to be a more strongly associated with hot spots. Findings suggest important differences between the cities' hot spots as well. They can be generalized by describing the NYC hot spots as working-class and middle-income communities, perhaps indicative of service workers and other occupations (including those classified as \"essential services\" during the pandemic) that may not require a college degree but pay wages above poverty levels. Chicago's hot spot neighborhoods, on the other hand, are among the city's most vulnerable, low-income neighborhoods with extremely high rates of poverty, unemployment, and non-Hispanic Black residents.","rel_num_authors":3,"rel_authors":[{"author_name":"Andrew R Maroko","author_inst":"CUNY Graduate School of Public Health and Health Policy"},{"author_name":"Denis Nash","author_inst":"CUNY Graduate School of Public Health and Health Policy"},{"author_name":"Brian Pavilonis","author_inst":"CUNY Graduate School of Public Health and Health Policy"},{"author_name":"Siyu Huang","author_inst":"Baidu Inc."},{"author_name":"Haozhe An","author_inst":"Baidu Inc."},{"author_name":"Qi Kang","author_inst":"Baidu Inc."},{"author_name":"Ying Li","author_inst":"Baidu Inc."},{"author_name":"Dejing Dou","author_inst":"Baidu Inc."},{"author_name":"Haifeng Wang","author_inst":"Baidu Inc."},{"author_name":"Jun Duan","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Xue Wang","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Linxiao Zhu","author_inst":"Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University"},{"author_name":"Shuliang Guo","author_inst":"the First Affiliated Hospital of Chongqing Medical University, Chongqing, China"},{"author_name":"Guicheng Wu","author_inst":"Department of Hepatopathy, Chongqing Three Gorges Central Hospital"},{"author_name":"Sherry Michelle Owen","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Barney S. Graham","author_inst":"National Institute of Health"},{"author_name":"Kizzmekia S. Corbett","author_inst":"National Institutes of Health"},{"author_name":"Natalie J. Thornburg","author_inst":"Centers for Disease Control and Prevention"},{"author_name":"Francois Anna","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Philippe Souque","author_inst":"Institut Pasteur"},{"author_name":"Marion Gransagne","author_inst":"Institut Pasteur"},{"author_name":"Jacques Bellalou","author_inst":"Institut Pasteur"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"public and global health"},{"rel_doi":"10.1101\/2020.04.21.20073833","rel_title":"Collateral damage: the impact on cancer outcomes of the COVID-19pandemic","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.21.20073833","rel_abs":"Background: Cancer diagnostics and surgery have been disrupted by the response of healthcare services to the COVID-19 pandemic. Progression of cancers during delay will impact on patient long-term survival. Methods: We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of three months and six months and periods of disruption of one year and two years. Using healthcare resource costing, we contextualise attributable lives saved and life years gained from cancer surgery to equivalent volumes of COVID-19 hospitalisations. Findings: Per year, 94,912 resections for major cancers result in 80,406 long-term survivors and 1,717,051 life years gained. Per-patient delay of six months would cause attributable death of 10,555 of these individuals with loss of 205,024 life years. For cancer surgery, average life years gained (LYGs) per patient are 18.1 under standard conditions and 15.9 with a delay of six months (a loss of 2.3 LYG per patient). Taking into account units of healthcare resource (HCRU), surgery results on average per patient in 2.25 resource-adjusted life years gained (RALYGs) under standard conditions and 1.98 RALYGs following delay of six months. For 94,912 hospital COVID-19 admissions, there are 474,505 LYGs requiring of 1,097,937 HCRUs. Hospitalisation of community-acquired COVID-19 patients yields on average per patient 5.0 LYG and 0.43 RALYGs. Interpretation: Delay of six months in surgery for incident cancers would mitigate 43% of life years gained by hospitalisation of an equivalent volume of admissions for community acquired COVID-19. This rises to 62% when considering resource-adjusted life-years gained. To avoid a downstream public health crisis of avoidable cancer deaths, cancer diagnostic and surgical pathways must be maintained at normal throughput, with rapid attention to any backlog already accrued. Funding: Breast Cancer Now, Cancer Research UK, Bobby Moore Fund for Cancer Research, National Institute for Health Research (NIHR)","rel_num_authors":22,"rel_authors":[{"author_name":"Amit Sud","author_inst":"Institute of Cancer Research"},{"author_name":"Michael E. Jones","author_inst":"Institute of Cancer Research"},{"author_name":"John Broggio","author_inst":"National Cancer Registration and Analysis Service, Public Health England"},{"author_name":"Chey Loveday","author_inst":"Institute of Cancer Research"},{"author_name":"Bethany Torr","author_inst":"Institute of Cancer Research"},{"author_name":"Alice Garrett","author_inst":"Institute of Cancer Research"},{"author_name":"David L. Nicol","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Shaman Jhanji","author_inst":"Royal Marsden NHS Foundation Trust; Institute of Cancer Research"},{"author_name":"Stephen A. Boyce","author_inst":"Oxford University Hospitals NHS Foundation Trust"},{"author_name":"Phillip Ward","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Jonathan M. Handy","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Nadia Yousaf","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"James Larkin","author_inst":"Royal Marsden NHS Foundation Trust; Institute of Cancer Research"},{"author_name":"Yae-Eun Suh","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Stephen Scott","author_inst":"RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust"},{"author_name":"Paul D.P. Pharoah","author_inst":"University of Cambridge"},{"author_name":"Charles Swanton","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Christopher Abbosh","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Matthew Williams","author_inst":"Imperial College Healthcare NHS Trust; Imperial College London"},{"author_name":"Georgios Lyratzopoulos","author_inst":"National Cancer Registration and Analysis Service, Public Health England; University College London"},{"author_name":"Richard Houlston","author_inst":"Institute of Cancer Research"},{"author_name":"Clare Turnbull","author_inst":"Institute of Cancer Research"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"oncology"},{"rel_doi":"10.1101\/2020.04.21.20063263","rel_title":"A web-based Diagnostic Tool for COVID-19 Using Machine Learning on Chest Radiographs (CXR)","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.21.20063263","rel_abs":"This paper reports the development and web deployment of an inference model for Coronavirus COVID-19 using machine vision on chest radiographs (CXR). The transfer learning from the Residual Network (RESNET-50) was leveraged for model development on CXR images from healthy individuals, bacterial and viral pneumonia, and COVID-19 positives patients. The performance metrics showed an accuracy of 99%, a recall valued of 99.8%, a precision of 99% and an F1 score of 99.8% for COVID-19 inference. The model was further successfully validated on CXR images from an independent repository. The implemented model was deployed with a web graphical user interface for inference (https:\/\/medics-inference.onrender.com ) for the medical research community; an associated cron job is scheduled to continue the learning process when novel and validated information becomes available","rel_num_authors":4,"rel_authors":[{"author_name":"Evariste Bosco Gueguim Kana","author_inst":"University of KwaZulu-Natal"},{"author_name":"Martiale Gaetan Zebaze Kana","author_inst":"Natural Science Sector, United Nations Educational, Scientific and Cultural Organization, 7 Place de Fontenoy, 75007 Paris, France"},{"author_name":"Armand F. Donfack Kana","author_inst":"Department of Computer Science, Ahmadu Bello University, Zaria, Nigeria"},{"author_name":"Roussel Hardo Azanfack Kenfack","author_inst":"University of South Africa"},{"author_name":"Bethany Torr","author_inst":"Institute of Cancer Research"},{"author_name":"Alice Garrett","author_inst":"Institute of Cancer Research"},{"author_name":"David L. Nicol","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Shaman Jhanji","author_inst":"Royal Marsden NHS Foundation Trust; Institute of Cancer Research"},{"author_name":"Stephen A. Boyce","author_inst":"Oxford University Hospitals NHS Foundation Trust"},{"author_name":"Phillip Ward","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Jonathan M. Handy","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Nadia Yousaf","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"James Larkin","author_inst":"Royal Marsden NHS Foundation Trust; Institute of Cancer Research"},{"author_name":"Yae-Eun Suh","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Stephen Scott","author_inst":"RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust"},{"author_name":"Paul D.P. Pharoah","author_inst":"University of Cambridge"},{"author_name":"Charles Swanton","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Christopher Abbosh","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Matthew Williams","author_inst":"Imperial College Healthcare NHS Trust; Imperial College London"},{"author_name":"Georgios Lyratzopoulos","author_inst":"National Cancer Registration and Analysis Service, Public Health England; University College London"},{"author_name":"Richard Houlston","author_inst":"Institute of Cancer Research"},{"author_name":"Clare Turnbull","author_inst":"Institute of Cancer Research"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"health informatics"},{"rel_doi":"10.1101\/2020.04.22.20070441","rel_title":"CT in relation to RT-PCR in diagnosing COVID-19 in the Netherlands: a prospective study","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.22.20070441","rel_abs":"Introduction Early differentiation between emergency department (ED) patients with and without corona virus disease (COVID-19) is very important. Chest CT scan may be helpful in early diagnosing of COVID-19. We investigated the diagnostic accuracy of CT using RT-PCR for SARS-CoV-2 as reference standard and investigated reasons for discordant results between the two tests. Methods In this prospective single centre study in the Netherlands, all adult symptomatic ED patients had both a CT scan and a PCR upon arrival at the ED. CT results were compared with PCR test(s). Diagnostic accuracy was calculated. Discordant results were investigated using discharge diagnoses. Results Between March 13th and March 24th 2020, 193 symptomatic ED patients were included. In total, 43.0% of patients had a positive PCR and 56.5% a positive CT, resulting in a sensitivity of 89.2%, specificity 68.2%, likelihoodratio (LR) + 2.81 and LR- 0.16. Sensitivity was higher in patients with high risk pneumonia (CURB-65 score [&ge;]3; n=17, 100%) and with sepsis (SOFA score [&ge;]2; n=137, 95.5%). Of the 35 patients (31.8%) with a suspicious CT and a negative PCR, 9 had another respiratory viral pathogen, and in 7 patients, COVID-19 was considered likely. One of nine patients with a non-suspicious CT and a positive PCR had developed symptoms within 48 hours before scanning. Discussion The accuracy of chest CT in symptomatic ED patients is high, but used as a single diagnostic test, CT can not safely diagnose or exclude COVID-19. However, CT can be used as a quick first screening tool.","rel_num_authors":9,"rel_authors":[{"author_name":"Hester A Gietema","author_inst":"Department of Radiology, Maastricht University Medical Centre, Grow school for oncology and developmental biology, Maastricht University, Maastricht"},{"author_name":"Noortje Zelis","author_inst":"Department of Internal Medicine, Division of General Internal Medicine, Section Acute Medicine, Maastricht University Medical Centre, CARIM School for Cardiovas"},{"author_name":"J. Martijn Nobel","author_inst":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre, School of Health Professions Education, Maastricht University, Maastricht, t"},{"author_name":"Lars J.G. Lambriks","author_inst":"Department of Internal Medicine, Division of General Internal Medicine, Section Acute Medicine, Maastricht University Medical Centre"},{"author_name":"Lieke B van Alphen","author_inst":"Department of Medical Microbiology, Maastricht University Medical Centre, School CAPHRI, Care and Public Health Research Institute, Maastricht University, Maast"},{"author_name":"Astrid M.L. Oude Lashof","author_inst":"Department of Medical Microbiology, Maastricht University Medical Centre, School of Nutrition and Translational Research in Metabolism, Maastricht University, M"},{"author_name":"Joachim E Wildberger","author_inst":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht"},{"author_name":"Irene C Nelissen","author_inst":"Department of Internal Medicine, Division of General Internal Medicine, Section Acute Medicine, Maastricht University Medical Centre, Maastricht"},{"author_name":"Patricia M Stassen","author_inst":"Department of Internal Medicine, Division of General Internal Medicine, Section Acute Medicine, Maastricht University Medical Centre, School CAPHRI, Care and Pu"},{"author_name":"Phillip Ward","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Jonathan M. Handy","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Nadia Yousaf","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"James Larkin","author_inst":"Royal Marsden NHS Foundation Trust; Institute of Cancer Research"},{"author_name":"Yae-Eun Suh","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Stephen Scott","author_inst":"RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust"},{"author_name":"Paul D.P. Pharoah","author_inst":"University of Cambridge"},{"author_name":"Charles Swanton","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Christopher Abbosh","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Matthew Williams","author_inst":"Imperial College Healthcare NHS Trust; Imperial College London"},{"author_name":"Georgios Lyratzopoulos","author_inst":"National Cancer Registration and Analysis Service, Public Health England; University College London"},{"author_name":"Richard Houlston","author_inst":"Institute of Cancer Research"},{"author_name":"Clare Turnbull","author_inst":"Institute of Cancer Research"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.04.21.20066258","rel_title":"No Clear Benefit to the Use of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019 : A Retrospective Cohort Study","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.21.20066258","rel_abs":"Background Coronavirus disease 2019 (COVID-19) is becoming an increasing global health issue which has spread across the globe. We aimed to study the effect of corticosteroids in the treatment of adult inpatients with COVID-19. Methods A retrospective cohort of 115 consecutive adult COVID-19 patients admitted to The Third Peoples Hospital of Hubei Province between Jan 18, 2020, and Feb 28, 2020 was analysed to study the effectiveness of corticosteroid. They were categorized according to whether or not corticosteroid therapy was given, and compared in terms of demographic characteristics, clinical features, laboratory indicators and clinical outcomes. The primary endpoint was defined as either mortality or intensive care unit (ICU) admission. Known adverse prognostic factors were used as covariates in multiple logistic regressions to adjust for their confounding effects on outcomes. Results Among 115 patients, 73 patients (63.5%) received corticosteroid. The levels of age, C-reactive protein, D-dimer and albumin were similar in both groups. The corticosteroid group had more adverse outcomes (32.9% vs. 11.9%) and statistically significant differences were observed (p=0.013). In multivariate analysis, corticosteroid treatment was associated with a 2.155-fold increase in risk of either mortality or ICU admission, although not statistically significant. Conclusion No evidence suggests that adult patients with COVID-19 will benefit from corticosteroids, and they might be more likely to be harmed with such treatment.","rel_num_authors":9,"rel_authors":[{"author_name":"Dan Wang","author_inst":"The Third Peoples Hospital of Hubei Province"},{"author_name":"Juan Wang","author_inst":"Department of Radiology, Tongji Hospital, Huazhong University of Science and Technology"},{"author_name":"Qunqun Jiang","author_inst":"Department of Infectious Diseases, Zhongnan Hospital of Wuhan University"},{"author_name":"Juan Yang","author_inst":"The Third Peoples Hospital of Hubei Province, Jianghan University"},{"author_name":"Jun Li","author_inst":"The Third Peoples Hospital of Hubei Province, Jianghan University"},{"author_name":"Chang Gao","author_inst":"The Third Peoples Hospital of Hubei Province, Jianghan University"},{"author_name":"Haiwei Jiang","author_inst":"The Third Peoples Hospital of Hubei Province, Jianghan University"},{"author_name":"Lintong Ge","author_inst":"The Third Peoples Hospital of Hubei Province, Jianghan University"},{"author_name":"Yongming Liu","author_inst":"The Third Peoples Hospital of Hubei Province, Jianghan University"},{"author_name":"Phillip Ward","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Jonathan M. Handy","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Nadia Yousaf","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"James Larkin","author_inst":"Royal Marsden NHS Foundation Trust; Institute of Cancer Research"},{"author_name":"Yae-Eun Suh","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Stephen Scott","author_inst":"RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust"},{"author_name":"Paul D.P. Pharoah","author_inst":"University of Cambridge"},{"author_name":"Charles Swanton","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Christopher Abbosh","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Matthew Williams","author_inst":"Imperial College Healthcare NHS Trust; Imperial College London"},{"author_name":"Georgios Lyratzopoulos","author_inst":"National Cancer Registration and Analysis Service, Public Health England; University College London"},{"author_name":"Richard Houlston","author_inst":"Institute of Cancer Research"},{"author_name":"Clare Turnbull","author_inst":"Institute of Cancer Research"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.04.19.20070870","rel_title":"Healthcare worker mask reuse in a global pandemic: Using idle resources to create an inexpensive, scalable, and accessible UV system for N95 sterilization","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.19.20070870","rel_abs":"As the current COVID-19 pandemic illustrates, not all hospitals and other facilities are equipped with enough personal protective equipment to meet the demand in a crisis. Healthcare workers around the world utilize N95 masks to protect themselves and their patients, yet during this global pandemic they are forced to re-wear what is intended to be single-use masks. This poses significant risk to these healthcare workers along with the populations they are trying to protect. Ultraviolet germicidal irradiation (UVGI) has been validated previously as a way to effectively sterilize these masks between use, however, not all facilities have access to the high cost commercial UV-C lamp sterilization equipment. However, UV-C bulbs are sitting idle in biosafety cabinets (BSCs) at universities and research facilities around the globe that have been shuttered to slow the spread of COVID-19. These bulbs may also be available in existing medical centers where infectious diseases are commonly treated. Therefore, we have developed a method to modify existing light fixtures, or create custom light fixtures compatible with new or existing common UV-C bulbs. This system is scalable and can be created for less than 50 US dollars, on site, at the point of need, and leverages resources that are currently untapped and sitting unused in public and private research facilities. The freely-accessible design can be easily modified for use around the world. Hospitals can obtain this potentially life-saving UVGI resource with minimal funds, via collaboration between research facilities to obtain the UV-C meters and limited availability UVGI bulbs. While mask reuse is not ideal, we must do what we can in emergency situations to protect our frontline healthcare workers and the communities they serve.","rel_num_authors":10,"rel_authors":[{"author_name":"Rachel M Gilbert","author_inst":"University of Delaware"},{"author_name":"Michael J Donzanti","author_inst":"University of Delaware"},{"author_name":"Daniel J Minahan","author_inst":"University of Delaware"},{"author_name":"Jasmine Shirazi","author_inst":"University of Delaware"},{"author_name":"Christine L Hatem","author_inst":"University of Delaware"},{"author_name":"Brielle Hayward-Piatkovskyi","author_inst":"University of Delaware"},{"author_name":"Allyson M Dang","author_inst":"University of Delaware"},{"author_name":"Katherine M Nelson","author_inst":"University of Delaware"},{"author_name":"Kimberly L Bothi","author_inst":"University of Delaware"},{"author_name":"Jason P Gleghorn","author_inst":"University of Delaware"},{"author_name":"Jonathan M. Handy","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Nadia Yousaf","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"James Larkin","author_inst":"Royal Marsden NHS Foundation Trust; Institute of Cancer Research"},{"author_name":"Yae-Eun Suh","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Stephen Scott","author_inst":"RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust"},{"author_name":"Paul D.P. Pharoah","author_inst":"University of Cambridge"},{"author_name":"Charles Swanton","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Christopher Abbosh","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Matthew Williams","author_inst":"Imperial College Healthcare NHS Trust; Imperial College London"},{"author_name":"Georgios Lyratzopoulos","author_inst":"National Cancer Registration and Analysis Service, Public Health England; University College London"},{"author_name":"Richard Houlston","author_inst":"Institute of Cancer Research"},{"author_name":"Clare Turnbull","author_inst":"Institute of Cancer Research"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"public and global health"},{"rel_doi":"10.1101\/2020.04.21.20072405","rel_title":"Statistical analysis of the impact of environmental temperature on the exponential growth rate of cases infected by COVID-19","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.21.20072405","rel_abs":"We perform a statistical analysis for understanding the effect of the environmental temperature on the exponential growth rate of the cases infected by COVID-19 for US and Italian regions. In particular, we analyze the datasets of regional infected cases, derive the growth rates for regions characterized by readable exponential growth phase in their evolution spread curve and plot them against the environmental temperatures averaged within the same regions, derive the relationship between temperature and growth rate, and evaluate its statistical confidence. The results clearly support the first reported statistically significant relationship of negative correlation between the average environmental temperature and exponential growth rates of the infected cases. The critical temperature, which eliminates the exponential growth, and thus the COVID-19 spread in US regions, is estimated to be Tc = 86.1 {+\/-} 4.3 F.","rel_num_authors":1,"rel_authors":[{"author_name":"George Livadiotis","author_inst":"Southwest Research Institute"},{"author_name":"Michael J Donzanti","author_inst":"University of Delaware"},{"author_name":"Daniel J Minahan","author_inst":"University of Delaware"},{"author_name":"Jasmine Shirazi","author_inst":"University of Delaware"},{"author_name":"Christine L Hatem","author_inst":"University of Delaware"},{"author_name":"Brielle Hayward-Piatkovskyi","author_inst":"University of Delaware"},{"author_name":"Allyson M Dang","author_inst":"University of Delaware"},{"author_name":"Katherine M Nelson","author_inst":"University of Delaware"},{"author_name":"Kimberly L Bothi","author_inst":"University of Delaware"},{"author_name":"Jason P Gleghorn","author_inst":"University of Delaware"},{"author_name":"Jonathan M. Handy","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Nadia Yousaf","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"James Larkin","author_inst":"Royal Marsden NHS Foundation Trust; Institute of Cancer Research"},{"author_name":"Yae-Eun Suh","author_inst":"Royal Marsden NHS Foundation Trust"},{"author_name":"Stephen Scott","author_inst":"RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust"},{"author_name":"Paul D.P. Pharoah","author_inst":"University of Cambridge"},{"author_name":"Charles Swanton","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Christopher Abbosh","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Matthew Williams","author_inst":"Imperial College Healthcare NHS Trust; Imperial College London"},{"author_name":"Georgios Lyratzopoulos","author_inst":"National Cancer Registration and Analysis Service, Public Health England; University College London"},{"author_name":"Richard Houlston","author_inst":"Institute of Cancer Research"},{"author_name":"Clare Turnbull","author_inst":"Institute of Cancer Research"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.04.22.20072124","rel_title":"Self-reported symptoms of covid-19 including symptoms most predictive of SARS-CoV-2 infection, are heritable","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.22.20072124","rel_abs":"Susceptibility to infection such as SARS-CoV-2 may be influenced by host genotype. TwinsUK volunteers (n=2633) completing the C-19 Covid symptom tracker app allowed classical twin studies of covid-19 symptoms including predicted covid-19, a symptom-based algorithm predicting true infection derived in app users tested for SARS-CoV-2. We found heritability for fever = 41 (95% confidence intervals 12-70)%; anosmia 47 (27-67)%; delirium 49 (24-75)%; and predicted covid-19 gave heritability = 50 (29-70)%.","rel_num_authors":14,"rel_authors":[{"author_name":"Frances MK Williams","author_inst":"King's College London"},{"author_name":"Maxim Freydin","author_inst":"King's College London"},{"author_name":"Massimo Mangino","author_inst":"King's College London"},{"author_name":"Simon Couvreur","author_inst":"King's College London"},{"author_name":"Alessia Visconti","author_inst":"King's College London"},{"author_name":"Ruth CE Bowyer","author_inst":"King's College London"},{"author_name":"Caroline I Le Roy","author_inst":"King's College London"},{"author_name":"Mario Falchi","author_inst":"King's College London"},{"author_name":"Carole Sudre","author_inst":"King's College London"},{"author_name":"Richard Davies","author_inst":"Zoe Global Ltd"},{"author_name":"Christopher Hammond","author_inst":"King's College London"},{"author_name":"Cristina Menni","author_inst":"King's College London"},{"author_name":"Claire Steves","author_inst":"King's College London"},{"author_name":"Tim Spector","author_inst":"King's College London"},{"author_name":"Stephen Scott","author_inst":"RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust"},{"author_name":"Paul D.P. Pharoah","author_inst":"University of Cambridge"},{"author_name":"Charles Swanton","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Christopher Abbosh","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Matthew Williams","author_inst":"Imperial College Healthcare NHS Trust; Imperial College London"},{"author_name":"Georgios Lyratzopoulos","author_inst":"National Cancer Registration and Analysis Service, Public Health England; University College London"},{"author_name":"Richard Houlston","author_inst":"Institute of Cancer Research"},{"author_name":"Clare Turnbull","author_inst":"Institute of Cancer Research"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"genetic and genomic medicine"},{"rel_doi":"10.1101\/2020.04.18.20070656","rel_title":"A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.18.20070656","rel_abs":"BACKGROUND: Coronavirus Disease 2019 (COVID-19) has recently become a public emergency and a worldwide pandemic. The clinical symptoms of severe and non-severe patients vary, and the case-fatality rate (CFR) in severe COVID-19 patients is very high. However, the information on the risk factors associated with the severity of COVID-19 and of their prognostic potential is limited. METHODS: In this retrospective study, the clinical characteristics, laboratory findings, treatment and outcome data were collected and analyzed from 223 COVID-19 patients stratified into 125 non-severe patients and 98 severe patients. In addition, a pooled large-scale meta-analysis of 1646 cases was performed. RESULTS: We found that the age, gender and comorbidities are the common risk factors associated with the severity of COVID-19. For the diagnosis markers, we found that the levels of D-dimer, C-reactive protein (CRP), lactate dehydrogenase (LDH), procalcitonin (PCT) were significantly higher in severe group compared with the non-severe group on admission (D-Dimer: 87.3% vs. 35.3%, P<0.001; CRP, 65.1% vs. 13.5%, P<0.001; LDH: 83.9% vs. 22.2%, P<0.001; PCT: 35.1% vs. 2.2%, P<0.001), while the levels of aspartate aminotransferase (ASP) and creatinine kinase (CK) were only mildly increased. We also made a large scale meta-analysis of 1646 cases combined with 4 related literatures, and further confirmed the relationship between the COVID-19 severity and these risk factors. Moreover, we tracked dynamic changes during the process of COVID-19, and found CRP, D-dimer, LDH, PCT kept in high levels in severe patient. Among all these markers, D-dimer increased remarkably in severe patients and mostly related with the case-fatality rate (CFR). We found adjuvant antithrombotic treatment in some severe patients achieved good therapeutic effect in the cohort. CONCLUSIONS: The diagnosis markers CRP, D-dimer, LDH and PCT are associated with severity of COVID-19. Among these markers, D-dimer is sensitive for both severity and CFR of COVID-19. Treatment with heparin or other anticoagulants may be beneficial for COVID-19 patients.","rel_num_authors":8,"rel_authors":[{"author_name":"Yongshent Huang","author_inst":"School of Basic Medicine Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences"},{"author_name":"Xiaoyu Lyu","author_inst":"Department of Endocrinology, the Central Hospital of Wuhan , Tongji Medical College, Huazhong University of Science and Technology"},{"author_name":"Dan Li","author_inst":"State Key Laboratory of Molecular Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Scie"},{"author_name":"Yujun Wang","author_inst":"Department of Critical care medicine, the Central Hospital of Wuhan , Tongji Medical College, Huazhong University of Science and Technology"},{"author_name":"Lin Wang","author_inst":"School of Basic Medicine Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences"},{"author_name":"Wenbin Zou","author_inst":"Department of Thoracic Surgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology"},{"author_name":"Yingxin Wei","author_inst":"Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"},{"author_name":"Xiaowei Wu","author_inst":"Department of Thoracic Surgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology"},{"author_name":"Carole Sudre","author_inst":"King's College London"},{"author_name":"Richard Davies","author_inst":"Zoe Global Ltd"},{"author_name":"Christopher Hammond","author_inst":"King's College London"},{"author_name":"Cristina Menni","author_inst":"King's College London"},{"author_name":"Claire Steves","author_inst":"King's College London"},{"author_name":"Tim Spector","author_inst":"King's College London"},{"author_name":"Stephen Scott","author_inst":"RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust"},{"author_name":"Paul D.P. Pharoah","author_inst":"University of Cambridge"},{"author_name":"Charles Swanton","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Christopher Abbosh","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Matthew Williams","author_inst":"Imperial College Healthcare NHS Trust; Imperial College London"},{"author_name":"Georgios Lyratzopoulos","author_inst":"National Cancer Registration and Analysis Service, Public Health England; University College London"},{"author_name":"Richard Houlston","author_inst":"Institute of Cancer Research"},{"author_name":"Clare Turnbull","author_inst":"Institute of Cancer Research"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.04.19.20071357","rel_title":"Immune defects and cardiovascular risk in X chromosome monosomy mosaicism mediated by loss of chromosome Y. A risk factor for SARS-CoV-2 vulnerability in elderly men?","rel_date":"2020-04-24","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.04.19.20071357","rel_abs":"The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) has an estimated overall case fatality ratio of 1.38% in China, being 53% higher in males and increasing exponentially with age. Mosaicism for X chromosome monosomy (XCM) shows a similar increase in aging population mostly driven by loss of chromosome Y in males (LOY), and is associated with a raise in all-cause mortality. Using comparative transcriptomic data, we have defined that XCM\/LOY is associated with abnormal peripheral blood cell counts with decreased progenitor cells and multiple biomarkers of immune system dysfunction, pro-coagulation activity and increased cardiovascular risk. Several differentially down-regulated genes in XCM\/LOY individuals are involved in the initial immune response to SARS-CoV-2 (OR of enrichment=7.23, p=1.5x10-7), mainly interferon-induced genes that code for inhibitors of viral processes. Thus, our data suggest that XCM mosaicism underlies at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential relevance for modulating prognosis and therapeutic response, we propose that evaluation of LOY and XCM by currently established methods should be implemented as biomarkers in infected patients, including currently ongoing clinical trials with different medications and vaccines for COVID-19. Testing for LOY\/XCM at large scale among elderly people may also be helpful to identify still unexposed people who may be especially vulnerable to severe Covid-19 disease.","rel_num_authors":4,"rel_authors":[{"author_name":"Luis A Perez-Jurado","author_inst":"Genetics Unit, Universitat Pompeu Fabra, Hospital del Mar Research Institute (IMIM)"},{"author_name":"Alejandro Caceres","author_inst":"ISGlobal"},{"author_name":"Tonu Esko","author_inst":"EGCUT"},{"author_name":"Juan R Gonzalez","author_inst":"Barcelona Institute for Global Health"},{"author_name":"Lin Wang","author_inst":"School of Basic Medicine Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences"},{"author_name":"Wenbin Zou","author_inst":"Department of Thoracic Surgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology"},{"author_name":"Yingxin Wei","author_inst":"Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"},{"author_name":"Xiaowei Wu","author_inst":"Department of Thoracic Surgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology"},{"author_name":"Carole Sudre","author_inst":"King's College London"},{"author_name":"Richard Davies","author_inst":"Zoe Global Ltd"},{"author_name":"Christopher Hammond","author_inst":"King's College London"},{"author_name":"Cristina Menni","author_inst":"King's College London"},{"author_name":"Claire Steves","author_inst":"King's College London"},{"author_name":"Tim Spector","author_inst":"King's College London"},{"author_name":"Stephen Scott","author_inst":"RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust"},{"author_name":"Paul D.P. Pharoah","author_inst":"University of Cambridge"},{"author_name":"Charles Swanton","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Christopher Abbosh","author_inst":"The Francis Crick Institute; University College London Cancer Institute"},{"author_name":"Matthew Williams","author_inst":"Imperial College Healthcare NHS Trust; Imperial College London"},{"author_name":"Georgios Lyratzopoulos","author_inst":"National Cancer Registration and Analysis Service, Public Health England; University College London"},{"author_name":"Richard Houlston","author_inst":"Institute of Cancer Research"},{"author_name":"Clare Turnbull","author_inst":"Institute of Cancer Research"},{"author_name":"Mireille Nowakowski","author_inst":"Institut Pasteur"},{"author_name":"Marija Backovic","author_inst":"Institut Pasteur"},{"author_name":"lila Bouadma","author_inst":"AP-HP"},{"author_name":"Lucie Le Fevre","author_inst":"AP-HP"},{"author_name":"Quentin Le Hingrat","author_inst":"AP-HP"},{"author_name":"Diane Descamps","author_inst":"AP-HP"},{"author_name":"Anabelle Pourbaix","author_inst":"AP-HP"},{"author_name":"Yazdan Yazdanpanah","author_inst":"AP-HP"},{"author_name":"Laura Tondeur","author_inst":"Institut Pasteur"},{"author_name":"Camille Besombes","author_inst":"Institut Pasteur"},{"author_name":"Marie-Noelle Ungeheuer","author_inst":"Institut Pasteur"},{"author_name":"Guillaume Mellon","author_inst":"AP-HP"},{"author_name":"Pascal Morel","author_inst":"EFS"},{"author_name":"Simon Rolland","author_inst":"AP-HP"},{"author_name":"Felix Rey","author_inst":"Institut Pasteur"},{"author_name":"Sylvie Behillil","author_inst":"Institut Pasteur"},{"author_name":"Vincent Enouf","author_inst":"Institut Pasteur"},{"author_name":"Audrey Lemaitre","author_inst":"Sante publique France"},{"author_name":"Marie-Aude Creach","author_inst":"CESPA"},{"author_name":"Stephane Petres","author_inst":"Institut Pasteur"},{"author_name":"Nicolas Escriou","author_inst":"Institut Pasteur"},{"author_name":"Pierre Charneau","author_inst":"Institut Pasteur - TheraVectys"},{"author_name":"Arnaud Fontanet","author_inst":"Institut Pasteur"},{"author_name":"Bruno Hoen","author_inst":"Institut Pasteur"},{"author_name":"Timothee Bruel","author_inst":"Institut Pasteur"},{"author_name":"Marc Eloit","author_inst":"Institut Pasteur"},{"author_name":"Hugo Mouquet","author_inst":"Institut Pasteur"},{"author_name":"Olivier Schwartz","author_inst":"Institut Pasteur"},{"author_name":"Sylvie van der Werf","author_inst":"Institut Pasteur"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"genetic and genomic medicine"}]}



